Xilio is focused on developing cytokines with exemplary clinical activity and tolerability. We are developing XTX202, a tumor-activated, engineered IL-2, for the treatment of advanced solid tumors.

About IL-2

IL-2, or Interleukin-2, is a type of cytokine that regulates the activities of white blood cells by binding to IL-2 receptors. IL-2 is currently used as a biological response modifier to boost the immune system in cancer therapy. Drug development of and treatment with IL-2 therapies has been limited due to severe systemic toxicity, including fatal outcomes.
 

XTX202, a tumor-activated IL-2

The critical challenge in the development of IL-2 therapeutics is to improve patient tolerability without reducing efficacy. XTX202 is an investigational tumor-activated beta-gamma biased (non-alpha), engineered IL-2 molecule designed to potently stimulate CD8+ effector T cells and natural killer (NK) cells without concomitant stimulation of regulatory T cells when activated (unmasked) in the tumor microenvironment.

XTX202: Pre-Clinical Studies

In preclinical studies, we observed that XTX202 was activated in a protease-dependent manner, exhibited tumor growth inhibition and was well-tolerated.

We are conducting a Phase 1 clinical trial evaluating XTX202 for the treatment of solid tumors. The Phase 1 trial is designed to evaluate the safety and tolerability of XTX202 as a monotherapy in patients with advanced solid tumors.